Press Releases
Newest First
All Years
Press Release
September 2, 2026
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
Press Release
August 17, 2026
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
Press Release
August 14, 2026
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Press Release
August 5, 2026
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Press Release
July 30, 2026
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
Press Release
July 16, 2026
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Press Release
July 13, 2026
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
Press Release
June 16, 2026
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Press Release
May 19, 2026
EyePoint Announces Participation at Upcoming Investor Conferences
Press Release
May 18, 2026